Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome

Shiratori, Souichi; Fujimoto, Katsuya; Nishimura, Masaharu; Hatanaka, Kanako C.; Kosugi-Kanaya, Mizuha; Okada, Ken-ichi; Sato, Junichi; Shigematsu, Akio; Hashimoto, Daigo; Endo, Tomoyuki; Kondo, Takeshi; Abe, Riichiro; Hashino, Satoshi; Matsuno, Yoshihiro; Shimizu, Hiroshi; Teshima, Takanori

doi:10.1002/hon.2162

Cited by 23 publications

(25 citation statements)

References 30 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A graft-versus-lymphoma effect was also demonstrated in CTCLs. Complete remissions have been achieved in patients relapsing after allo-HCT by prescribing donor lymphocyte infusions [31,32]. This graft-versus-lymphoma effect is perhaps another reason that explains the increased use of RIC and NMA conditioning allo-HCT regimens in CTCLs.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis

Iqbal

Reljic

Ayala

et al. 2020

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Mycosis fungoides and S ezary syndrome are the most common types of primary cutaneous T cell lymphomas. The clinical presentation of mycosis fungoides is generally indolent, whereas S ezary syndrome represents a more aggressive disease variant. Stage at diagnosis is the most important determinant of long-term survival outcome. Although most patients present with early-stage disease, those who develop progressive disease or have an advanced stage represent a therapeutic challenge because of a lack of effective therapies. Allogeneic hematopoietic cell transplantation (allo-HCT) has been used as a potentially curative treatment modality with encouraging long-term outcomes. However, a lack of randomized controlled data remains, and the published literature is limited to mostly retrospective studies. We performed a comprehensive search of the medical literature using PubMed/Medline, EMBASE, and Cochrane reviews on September 13, 2018. We extracted data on clinical outcomes related to benefits (overall [OS] and progression-free [PFS] survival) and harms (relapse and nonrelapse mortality [NRM]) independently by 2 authors. Our search strategy identified 289 references. Five studies (266 patients) were included in this systematic review and meta-analysis. Reduced-intensity and nonmyeloablative regimens were more commonly prescribed (76%). Mobilized peripheral blood stem cells were the preferred graft source (78%). The pooled OS and PFS rates were 59% (95% confidence interval [CI], 50% to 69%) and 36% (95% CI, 27% to 45%), respectively. Pooled relapse rate was 47% (95% CI, 41% to 53%) and pooled NRM rate 19% (95% CI, 13% to 27%). Results of this systematic review and meta-analysis show that allo-HCT yields encouraging OS and PFS rates; however; relapse remains a significant cause of allo-HCT failure. Novel strategies to further improve outcomes should focus on offering allo-HCT before the development of resistant disease and reducing relapse by incorporating post-transplant maintenance therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis

Iqbal

Reljic

Ayala

et al. 2020

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

show abstract

“…To date, six patients with MF/SS have been reported to undergo DLI after allogeneic HSCT . Of these, three patients achieved CR, two obtained PR and one died of the disease after DLI . DLI seems to be effective in the treatment of post‐transplant relapse of MF/SS.…”

Section: Discussionmentioning

confidence: 99%

Hematopoietic stem cell transplantation in advanced cutaneous T‐cell lymphoma

Saruta

Ohata

Muto

et al. 2017

The Journal of Dermatology

View full text Add to dashboard Cite

We retrospectively reviewed data pertaining to five patients with cutaneous T-cell lymphoma (CTCL) who had received hematopoietic stem cell transplantation (HSCT) between 2004 and 2015 at Kurume University Hospital, along with their clinical data until March 2016. For patients with advanced CTCL eligible for HSCT, autologous HSCT was performed when they responded well to chemotherapy, and allogeneic HSCT was selected for patients with advanced mycosis fungoides (MF)/Sézary syndrome (SS) and CTCL other than MF/SS with poor chemosensitivity. Two patients (primary cutaneous anaplastic large cell lymphoma and primary cutaneous CD8 aggressive epidermotropic cytotoxic T-cell lymphoma) who responded well to chemotherapy received autologous HSCT: one patient was alive in partial remission and the other died due to therapy-related acute myeloid leukemia without disease relapse. In the remaining three patients with MF or SS, allogeneic HSCT was performed. Although one patient with MF died due to disease progression, the remaining two patients were alive in complete remission. Although there were two deaths in this study, the outcomes were considered satisfactory.

show abstract

“…Several case reports and series have been published since then as indicated in Table 1. 18,[36][37][38][39][40][41][42][43][44][45][46] However, the experience of allogeneic transplant for treatment of MF/SS is limited to small retrospective studies with small number of patients usually lumped together with transplant data for subtypes of T cell and other NHL. The following discussion attempts to tease out data specific to CTCL and its subtypes.…”

Section: Allogeneic Stem Cell Transplant For Mycosis Fungoides and Sémentioning

confidence: 97%

Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome

Virmani

Zain

Rosen

et al. 2015

Dermatologic Clinics

View full text Add to dashboard Cite

Mycosis fungoides (MF) and Sézary syndrome (SS) are common types of primary cutaneous T-cell lymphoma. Early-stage MF has a favorable prognosis and responds well to skin-directed regimens. Patients with advanced-stage MF, transformed MF, and SS are treated with combined systemic and skin-directed therapies. However, the disease is incurable with standard regimens, and frequent relapses are common. Owing to the lack of improvement in overall survival with standard regimens, hematopoietic stem cell transplant (HSCT) has been explored as a potential curative option. This article reviews the role of HSCT in MF/SS and discusses data regarding conditioning regimens, treatment-related complications, and outcomes.

show abstract

Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome

Cited by 23 publications

References 30 publications

Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis

Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis

Hematopoietic stem cell transplantation in advanced cutaneous T‐cell lymphoma

Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome

Contact Info

Product

Resources

About